Literature DB >> 14633405

A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells.

Gudrun Schiedner1, Wilhelm Bloch, Sabine Hertel, Marion Johnston, Andrei Molojavyi, Volker Dries, Georg Varga, Nico Van Rooijen, Stefan Kochanek.   

Abstract

Intravascular injection of adenoviral vectors may result in a toxic and potentially lethal reaction, the mechanism of which is poorly understood. We noted that mice demonstrated a transient change in behavior that was characterized by inactivity and lethargy within minutes after intravenous injection of relatively low doses of adenoviral vectors (including high-capacity gutless vectors). Moreover, immediately after vector injection a significant drop in blood pressure was measured that most probably was caused by the systemic activation of endothelial cells as monitored by detection of phosphorylated Akt/PKB kinase, activated endothelial nitric oxide synthase (eNOS), and nitrotyrosine. The activation of the endothelium was the result of the interaction of viral particles with Kupffer cells, which are resident macrophages of the liver representing the first line of defense of the innate immune system. Surprisingly, the uptake of vector particles by Kupffer cells not only resulted in their strong activation, but also in their nearly complete disappearance from the liver. Our results suggest that the toxicity of intravenously injected adenoviral vectors may be directly linked to the activation and destruction of Kupffer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633405     DOI: 10.1089/104303403322542275

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  45 in total

1.  Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

3.  Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection.

Authors:  Daniel M Lipinski; Chris A Reid; Sanford L Boye; James J Peterson; Xiaoping Qi; Shannon E Boye; Michael E Boulton; William W Hauswirth
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

4.  Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

5.  Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting.

Authors:  Debadyuti Ghosh; Michael A Barry
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 6.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 7.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.

Authors:  Sabine Boeckle; Ernst Wagner
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

9.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

10.  Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor.

Authors:  Zhili Xu; Jeffrey S Smith; Jie Tian; Andrew P Byrnes
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.